» Articles » PMID: 34680325

Could Photodynamic Therapy Be a Promising Therapeutic Modality in Hepatocellular Carcinoma Patients? A Critical Review of Experimental and Clinical Studies

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2021 Oct 23
PMID 34680325
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Photodynamic Therapy (PDT) relies on local or systemic administration of a light-sensitive dye, called photosensitizer, to accumulate into the target site followed by excitation with light of appropriate wavelength and fluence. This photo-activated molecule reacts with the intracellular oxygen to induce selective cytotoxicity of targeted cells by the generation of reactive oxygen species. Hepatocellular carcinoma (HCC), one of the leading causes of cancer-associated mortality worldwide, has insufficient treatment options available. In this review, we discuss the mechanism and merits of PDT along with its recent developments as an anti-cancerous therapy. We also highlight the application of this novel therapy for diagnosis, visualization, and treatment of HCC. We examine the underlying challenges, some pre-clinical and clinical studies, and possibilities of future studies associated with PDT. Finally, we discuss the mechanism of an active immune response by PDT and thereafter explored the role of PDT in the generation of anti-tumor immune response in the context of HCC, with an emphasis on checkpoint inhibitor-based immunotherapy. The objective of this review is to propose PDT as a plausible adjuvant to existing therapies for HCC, highlighting a feasible combinatorial approach for HCC treatment.

Citing Articles

Photodynamic Therapy in Cancer: Insights into Cellular and Molecular Pathways.

Papa V, Furci F, Minciullo P, Casciaro M, Allegra A, Gangemi S Curr Issues Mol Biol. 2025; 47(2).

PMID: 39996790 PMC: 11854756. DOI: 10.3390/cimb47020069.


MMP-2-triggered, mitochondria-targeted PROTAC-PDT therapy of breast cancer and brain metastases inhibition.

Tong F, Wang Y, Xu Y, Zhou Y, He S, Du Y Nat Commun. 2024; 15(1):10382.

PMID: 39613781 PMC: 11607387. DOI: 10.1038/s41467-024-54854-2.


Enhancing cancer immunotherapy with photodynamic therapy and nanoparticle: making tumor microenvironment hotter to make immunotherapeutic work better.

Thiruppathi J, Vijayan V, Park I, Lee S, Rhee J Front Immunol. 2024; 15:1375767.

PMID: 38646546 PMC: 11026591. DOI: 10.3389/fimmu.2024.1375767.


Hemin blocks TIGIT/PVR interaction and induces ferroptosis to elicit synergistic effects of cancer immunotherapy.

Zhou X, Li Y, Zhang X, Li B, Jin S, Wu M Sci China Life Sci. 2024; 67(5):996-1009.

PMID: 38324132 DOI: 10.1007/s11427-023-2472-4.


Photodynamic Therapy Combined with Ferroptosis Is a Synergistic Antitumor Therapy Strategy.

Huang Y, Li X, Zhang Z, Xiong L, Wang Y, Wen Y Cancers (Basel). 2023; 15(20).

PMID: 37894410 PMC: 10604985. DOI: 10.3390/cancers15205043.


References
1.
Garg A, Krysko D, Vandenabeele P, Agostinis P . Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin. Cancer Immunol Immunother. 2011; 61(2):215-221. PMC: 11029694. DOI: 10.1007/s00262-011-1184-2. View

2.
Huang Z . A review of progress in clinical photodynamic therapy. Technol Cancer Res Treat. 2005; 4(3):283-93. PMC: 1317568. DOI: 10.1177/153303460500400308. View

3.
Garg A, Nowis D, Golab J, Agostinis P . Photodynamic therapy: illuminating the road from cell death towards anti-tumour immunity. Apoptosis. 2010; 15(9):1050-71. DOI: 10.1007/s10495-010-0479-7. View

4.
Vermandel M, Dupont C, Lecomte F, Leroy H, Tuleasca C, Mordon S . Standardized intraoperative 5-ALA photodynamic therapy for newly diagnosed glioblastoma patients: a preliminary analysis of the INDYGO clinical trial. J Neurooncol. 2021; 152(3):501-514. DOI: 10.1007/s11060-021-03718-6. View

5.
Grandhi M, Kim A, Ronnekleiv-Kelly S, Kamel I, Ghasebeh M, Pawlik T . Hepatocellular carcinoma: From diagnosis to treatment. Surg Oncol. 2016; 25(2):74-85. DOI: 10.1016/j.suronc.2016.03.002. View